The global guillain barre syndrome diagnostics market size is accounted at USD 154.02 million in 2025 and is forecasted to hit around USD 200.96 million by 2034, representing a CAGR of 3.00% from 2025 to 2034. Asia Pacific market size was estimated at USD 62.80 million in 2024 and is expanding at a CAGR of 3.12% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Guillain-Barre Syndrome Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Guillain-Barre Syndrome Diagnostics Market, by Test
8.1.1. Lumbar Puncture
8.1.1.1. Market Revenue and Forecast
8.1.2. Electromyography
8.1.2.1. Market Revenue and Forecast
8.1.3. Nerve Conduction
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Guillain-Barre Syndrome Diagnostics Market, by End-use
9.1.1. Hospitals and Clinics
9.1.1.1. Market Revenue and Forecast
9.1.2. Diagnostic Laboratories
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test
10.1.2. Market Revenue and Forecast, by End-use
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test
10.1.3.2. Market Revenue and Forecast, by End-use
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test
10.1.4.2. Market Revenue and Forecast, by End-use
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test
10.2.2. Market Revenue and Forecast, by End-use
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test
10.2.3.2. Market Revenue and Forecast, by End-use
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test
10.2.4.2. Market Revenue and Forecast, by End-use
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test
10.2.5.2. Market Revenue and Forecast, by End-use
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test
10.2.6.2. Market Revenue and Forecast, by End-use
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test
10.3.2. Market Revenue and Forecast, by End-use
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test
10.3.3.2. Market Revenue and Forecast, by End-use
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test
10.3.4.2. Market Revenue and Forecast, by End-use
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test
10.3.5.2. Market Revenue and Forecast, by End-use
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test
10.3.6.2. Market Revenue and Forecast, by End-use
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test
10.4.2. Market Revenue and Forecast, by End-use
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test
10.4.3.2. Market Revenue and Forecast, by End-use
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test
10.4.4.2. Market Revenue and Forecast, by End-use
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test
10.4.5.2. Market Revenue and Forecast, by End-use
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test
10.4.6.2. Market Revenue and Forecast, by End-use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test
10.5.2. Market Revenue and Forecast, by End-use
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test
10.5.3.2. Market Revenue and Forecast, by End-use
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test
10.5.4.2. Market Revenue and Forecast, by End-use
11.1. Cadwell Industries, Inc
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bionen Medical Devices
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Deymed Diagnostic
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Neurosoft
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Alpine Biomed
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Natus Medical Incorporated
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Nihon Kohden Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Medtronic plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. EMS Biomedical
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Rochester Electro-Medical, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client